Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Conditions
Interventions
Intervention1: Inj. Sepsivac: 0.3 ml/day of Inj. Sepsivac will be administered as intra-dermal injections for three consecutive days as 0.1ml x 3 injections at different sites along with standard ther
Sponsors
R D Gardi Medical College
Eligibility
Inclusion criteria
Inclusion criteria: Patients between the age of 18 â?? 65 years diagnosed to have Covid19 infection confirmed by RTPCR assay, and any one or more of the following 1. Either an oxygen saturation of 94% or less while the patient was breathing ambient air or a need for oxygen support 2. Creatinine clearance above 30 ml per minute 3. Serum levels of ALT and AST less than five times the upper limit of the normal range 4. Requirement of vasopressor
Exclusion criteria
Exclusion criteria: 1. Pregnant or nursing female. 2. Patient previously enrolled into similar study. 3. Patient participating or having participated in a clinical trial with another investigational drug within the last 28 days except for investigational drugs against cancer, leukaemia or HIV. 4. Patients not likely to complete the trial as per judgment of the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical improvement, as defined by live discharge from the hospital, a decrease of at least 2 points from baseline on a modified ordinal scale (as recommended by the WHO R&D Blueprint Group) Conversion of Covid19 status to negativeTimepoint: 28 days | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Overall safety of the study drug 2. Duration of hospitalization 3. Improvement in the abnormal laboratory values Timepoint: 28 days | — |
Countries
India
Contacts
Public ContactDr Ashish Pathak
R D Gardi Medical College
Outcome results
None listed